Vischer advised Meininger on the deal. International hotel group Meininger managed its successful market entry in Switzerland and opens new hotels in Zurich (174 rooms, 582 beds)...
Meininger’s Opening New Hotels in Switzerland
XOMA’s Acquisition of Royalty and Milestone Interest in Checkmate’s Vidutolimod from Kuros Biosciences
Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest...
TargImmune Therapeutics’ CHF 17.7 Million Financing Round
VISCHER has advised TargImmune on the deal. TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused...
Novartis’ Collaboration Agreement With Cellerys
VISCHER AG has advised Novartis AG in this transaction. Novartis has signed a collaboration agreement and an option to acquire Cellerys. The Zurich-based startup is researching...
Dermavant Sciences’ $200 Million Financing
VISCHER acted as Swiss counsel to Dermavant in the transaction. Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, entered...
Swiss Nuclides’ CHF 2.6 Million Series A Financing Round
Vischer assisted Swiss Nuclides in this transaction . Swiss Nuclides AG, a developer of novel radionuclide PET tracers for the precision diagnostics, has raised CHF 2.6m...
UMB Solutions AG’s Acquisition of Ubitec AG
Vischer advised the sellers on all legal aspects of the transaction. ubitec AG, a developer of innovative software solutions for digitization, was acquired by UMB Solutions...
DomoSafety’s Serie B Financing Round
VISCHER advised DomoSafety SA on the transaction. DomoSafety SA, a leading company in the digital health segment developing innovative solutions in the field of patient safety,...
Haya Therapeutics’ CHF 18 Million Seed Round
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...
Haya Therapeutics’ CHF 18 Million Seed Round
VISCHER advised Haya Therapeutics SA on all legal issues related to the financing round. HAYA Therapeutics SA, a company developing precision medicines that target tissue and...
Relief Therapeutics’ Acquisition of Applied Pharma Research S.A.
VISCHER advises Relief Therapeutics regarding all legal aspects of this transaction. RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced...
Oculis SA’s $57 Million Series C Financing Round
Vischer advised Oculis SA on the deal, while Walder Wyss advised Hyfinity Investments. Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to...